The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Ayalew Tefferi

Division of Hematology

Department of Medicine

Mayo Clinic




Name/email consistency: high



  • Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, USA. 2000 - 2013
  • Mayo Clinic, 200 First St SW, Rochester, MN 55905;. 2011
  • Mayo Clinic, Rochester, USA. 2009
  • Department of Internal Medicine and Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA. 2005
  • Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA. 2005
  • Mayo Clinic, 200 First Street SW, West 10 A, Division of Hematology, USA. E-mail:. 2004


  1. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Tefferi, A. Am. J. Hematol. (2013) [Pubmed]
  2. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Tefferi, A. Am. J. Hematol. (2012) [Pubmed]
  3. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. Pardanani, A., Lasho, T.L., Finke, C.M., Rajkumar, S.V., Singh, P.P., Ketterling, R.P., Hanson, C.A., Katzmann, J.A., Tefferi, A. J. Clin. Oncol. (2012) [Pubmed]
  4. Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Tefferi, A., Letendre, L. Am. J. Hematol. (2011) [Pubmed]
  5. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. Barbui, T., Thiele, J., Passamonti, F., Rumi, E., Boveri, E., Ruggeri, M., Rodeghiero, F., d'Amore, E.S., Randi, M.L., Bertozzi, I., Marino, F., Vannucchi, A.M., Antonioli, E., Carrai, V., Gisslinger, H., Buxhofer-Ausch, V., Müllauer, L., Carobbio, A., Gianatti, A., Gangat, N., Hanson, C.A., Tefferi, A. J. Clin. Oncol. (2011) [Pubmed]
  6. How I treat myelofibrosis. Tefferi, A. Blood (2011) [Pubmed]
  7. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management. Tefferi, A. Am. J. Hematol. (2011) [Pubmed]
  8. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. Tefferi, A., Vaidya, R., Caramazza, D., Finke, C., Lasho, T., Pardanani, A. J. Clin. Oncol. (2011) [Pubmed]
  9. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. Tefferi, A., Vainchenker, W. J. Clin. Oncol. (2011) [Pubmed]
  10. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Tefferi, A., Gotlib, J., Pardanani, A. Mayo Clin. Proc. (2010) [Pubmed]
  11. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. Tefferi, A., Siragusa, S., Hussein, K., Schwager, S.M., Hanson, C.A., Pardanani, A., Cervantes, F., Passamonti, F. Am. J. Hematol. (2010) [Pubmed]
  12. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Tefferi, A., Lasho, T.L., Patnaik, M.M., Finke, C.M., Hussein, K., Hogan, W.J., Elliott, M.A., Litzow, M.R., Hanson, C.A., Pardanani, A. Leukemia (2010) [Pubmed]
  13. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Tefferi, A., Lasho, T.L., Abdel-Wahab, O., Guglielmelli, P., Patel, J., Caramazza, D., Pieri, L., Finke, C.M., Kilpivaara, O., Wadleigh, M., Mai, M., McClure, R.F., Gilliland, D.G., Levine, R.L., Pardanani, A., Vannucchi, A.M. Leukemia (2010) [Pubmed]
  14. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Tefferi, A. Leukemia (2010) [Pubmed]
  15. Leukocytosis as a risk factor for thrombosis in myeloproliferative neoplasms-biologically plausible but clinically uncertain. Tefferi, A. Am. J. Hematol. (2010) [Pubmed]
  16. Targeted therapy in KITD816V-positive mastocytosis: waiting for proof-of-principle. Tefferi, A., Pardanani, A. Leuk. Lymphoma (2010) [Pubmed]
  17. Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices. Tefferi, A. Leuk. Lymphoma (2010) [Pubmed]
  18. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. Tefferi, A., Mesa, R.A., Pardanani, A., Hussein, K., Schwager, S., Hanson, C.A., Steensma, D.P. Am. J. Hematol. (2009) [Pubmed]
  19. Oligonucleotide array CGH studies in myeloproliferative neoplasms: comparison with JAK2V617F mutational status and conventional chromosome analysis. Tefferi, A., Sirhan, S., Sun, Y., Lasho, T., Finke, C.M., Weisberger, J., Bale, S., Compton, J., LeDuc, C.A., Pardanani, A., Thorland, E.C., Shevchenko, Y., Grodman, M., Chung, W.K. Leuk. Res. (2009) [Pubmed]
  20. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. Tefferi, A., Verstovsek, S., Barosi, G., Passamonti, F., Roboz, G.J., Gisslinger, H., Paquette, R.L., Cervantes, F., Rivera, C.E., Deeg, H.J., Thiele, J., Kvasnicka, H.M., Vardiman, J.W., Zhang, Y., Bekele, B.N., Mesa, R.A., Gale, R.P., Kantarjian, H.M. J. Clin. Oncol. (2009) [Pubmed]
  21. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Tefferi, A., Pardanani, A., Lim, K.H., Abdel-Wahab, O., Lasho, T.L., Patel, J., Gangat, N., Finke, C.M., Schwager, S., Mullally, A., Li, C.Y., Hanson, C.A., Mesa, R., Bernard, O., Delhommeau, F., Vainchenker, W., Gilliland, D.G., Levine, R.L. Leukemia (2009) [Pubmed]
  22. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Tefferi, A., Levine, R.L., Lim, K.H., Abdel-Wahab, O., Lasho, T.L., Patel, J., Finke, C.M., Mullally, A., Li, C.Y., Pardanani, A., Gilliland, D.G. Leukemia (2009) [Pubmed]
  23. Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. Tefferi, A. J. Cell. Mol. Med. (2009) [Pubmed]
  24. JAK2V617F: more than a clonal marker?. Tefferi, A. Leuk. Lymphoma (2009) [Pubmed]
  25. Myeloproliferative neoplasms: thrombophilic clonal stem cell diseases. Tefferi, A. Cancer Treat. Res. (2009) [Pubmed]
  26. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Tefferi, A., Thiele, J., Vardiman, J.W. Cancer (2009) [Pubmed]
  27. Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations. Tefferi, A., Passamonti, F. Am. J. Hematol. (2009) [Pubmed]
  28. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Tefferi, A., Skoda, R., Vardiman, J.W. Nature Reviews. Clinical Oncology (2009) [Pubmed]
  29. Myelodysplastic syndromes. Tefferi, A., Vardiman, J.W. N. Engl. J. Med. (2009) [Pubmed]
  30. 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis. Tefferi, A., Gangat, N., Wolanskyj, A.P., Schwager, S., Pardanani, A., Lasho, T.L., Mesa, R., McClure, R.F., Li, C.Y., Hanson, C.A. Eur. J. Haematol. (2008) [Pubmed]
  31. The history of myeloproliferative disorders: before and after Dameshek. Tefferi, A. Leukemia (2008) [Pubmed]
  32. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Tefferi, A., Vardiman, J.W. Leukemia (2008) [Pubmed]
  33. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Tefferi, A., Lasho, T.L., Huang, J., Finke, C., Mesa, R.A., Li, C.Y., Wu, W., Hanson, C.A., Pardanani, A. Leukemia (2008) [Pubmed]
  34. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Tefferi, A. Am. J. Hematol. (2008) [Pubmed]
  35. Is chronic myelomonocytic leukemia more akin to myelodysplastic or myeloproliferative neoplasms and does it matter?. Tefferi, A. Leuk. Lymphoma (2008) [Pubmed]
  36. Idiopathic erythrocytosis: a non-entity?. Tefferi, A. Leuk. Lymphoma (2008) [Pubmed]
  37. Epigenetic alterations and anti-epigenetic therapy in myelofibrosis. Tefferi, A. Leuk. Lymphoma (2008) [Pubmed]
  38. Evaluation of "increased" hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests. Tefferi, A., Pardanani, A. Mayo Clin. Proc. (2007) [Pubmed]
  39. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Tefferi, A., Elliott, M. Semin. Thromb. Hemost. (2007) [Pubmed]
  40. JAK2 mutations and clinical practice in myeloproliferative neoplasms. Tefferi, A. Cancer. J (2007) [Pubmed]
  41. The diagnostic interface between histology and molecular tests in myeloproliferative disorders. Tefferi, A., Vardiman, J.W. Curr. Opin. Hematol. (2007) [Pubmed]
  42. Suppressors of cytokine signaling and regulation of clonal erythropoiesis. Tefferi, A. Leuk. Lymphoma (2007) [Pubmed]
  43. Oncogenes in myeloproliferative disorders. Tefferi, A., Gilliland, D.G. Cell. Cycle (2007) [Pubmed]
  44. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Tefferi, A., Huang, J., Schwager, S., Li, C.Y., Wu, W., Pardanani, A., Mesa, R.A. Cancer (2007) [Pubmed]
  45. Microcytosis in agnogenic myeloid metaplasia: prevalence and clinical correlates. Tefferi, A., Dingli, D., Li, C.Y., Mesa, R.A. Leuk. Res. (2006) [Pubmed]
  46. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Tefferi, A., Lasho, T.L., Schwager, S.M., Strand, J.S., Elliott, M., Mesa, R., Li, C.Y., Wadleigh, M., Lee, S.J., Gilliland, D.G. Cancer (2006) [Pubmed]
  47. New insights into the pathogenesis and drug treatment of myelofibrosis. Tefferi, A. Curr. Opin. Hematol. (2006) [Pubmed]
  48. Essential thrombocythemia: scientific advances and current practice. Tefferi, A. Curr. Opin. Hematol. (2006) [Pubmed]
  49. Mutation screening for JAK2V617F: when to order the test and how to interpret the results. Tefferi, A., Pardanani, A. Leuk. Res. (2006) [Pubmed]
  50. Iron chelation therapy for myelodysplastic syndrome: if and when. Tefferi, A. Mayo Clin. Proc. (2006) [Pubmed]
  51. Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy. Tefferi, A., Strand, J.J., Lasho, T.L., Elliott, M.A., Li, C.Y., Mesa, R.A., Dewald, G.W. Cancer (2006) [Pubmed]
  52. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Tefferi, A., Cortes, J., Verstovsek, S., Mesa, R.A., Thomas, D., Lasho, T.L., Hogan, W.J., Litzow, M.R., Allred, J.B., Jones, D., Byrne, C., Zeldis, J.B., Ketterling, R.P., McClure, R.F., Giles, F., Kantarjian, H.M. Blood (2006) [Pubmed]
  53. Atypical myeloproliferative disorders: diagnosis and management. Tefferi, A., Elliott, M.A., Pardanani, A. Mayo Clin. Proc. (2006) [Pubmed]
  54. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Tefferi, A., Barosi, G., Mesa, R.A., Cervantes, F., Deeg, H.J., Reilly, J.T., Verstovsek, S., Dupriez, B., Silver, R.T., Odenike, O., Cortes, J., Wadleigh, M., Solberg, L.A., Camoriano, J.K., Gisslinger, H., Noel, P., Thiele, J., Vardiman, J.W., Hoffman, R., Cross, N.C., Gilliland, D.G., Kantarjian, H. Blood (2006) [Pubmed]
  55. Eosinophilia: secondary, clonal and idiopathic. Tefferi, A., Patnaik, M.M., Pardanani, A. Br. J. Haematol. (2006) [Pubmed]
  56. Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system. Tefferi, A., Gilliland, G. Best. Pract. Res. Clin. Haematol (2006) [Pubmed]
  57. The diagnosis of polycythemia vera: new tests and old dictums. Tefferi, A. Best. Pract. Res. Clin. Haematol (2006) [Pubmed]
  58. Is bone marrow biopsy essential for the diagnosis of essential thrombocythemia?. Tefferi, A. Leuk. Lymphoma (2006) [Pubmed]
  59. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Tefferi, A. Hematology. Am. Soc. Hematol. Educ. Program (2006) [Pubmed]
  60. Genomics basics: DNA structure, gene expression, cloning, genetic mapping, and molecular tests. Tefferi, A. Semin. Cardiothorac. Vasc. Anesth (2006) [Pubmed]
  61. Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment. Tefferi, A. Mayo Clin. Proc. (2005) [Pubmed]
  62. The indolent natural history of essential thrombocythemia: a challenge to new drug development. Tefferi, A. Mayo Clin. Proc. (2005) [Pubmed]
  63. JAK2 in myeloproliferative disorders is not just another kinase. Tefferi, A., Gilliland, D.G. Cell. Cycle (2005) [Pubmed]
  64. Modern diagnosis and treatment of primary eosinophilia. Tefferi, A. Acta Haematol. (2005) [Pubmed]
  65. Introduction to a cancer symposium for the practitioner. Tefferi, A., Rajkumar, S.V., Adjei, A.A. Mayo Clin. Proc. (2005) [Pubmed]
  66. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia. Tefferi, A., Dingli, D., Li, C.Y., Dewald, G.W. Cancer (2005) [Pubmed]
  67. bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment. Tefferi, A., Barbui, T. Mayo Clin. Proc. (2005) [Pubmed]
  68. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Tefferi, A., Sirhan, S., Lasho, T.L., Schwager, S.M., Li, C.Y., Dingli, D., Wolanskyj, A.P., Steensma, D.P., Mesa, R., Gilliland, D.G. Br. J. Haematol. (2005) [Pubmed]
  69. Polycythemia vera: scientific advances and current practice. Tefferi, A., Spivak, J.L. Semin. Hematol. (2005) [Pubmed]
  70. Pathogenesis of myelofibrosis with myeloid metaplasia. Tefferi, A. J. Clin. Oncol. (2005) [Pubmed]
  71. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Tefferi, A., Pardanani, A. Curr. Opin. Hematol. (2004) [Pubmed]
  72. Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. Tefferi, A., Lasho, T.L., Wolanskyj, A.P., Mesa, R.A. Blood (2004) [Pubmed]
  73. Systemic mastocytosis: current concepts and treatment advances. Tefferi, A., Pardanani, A. Curr. Hematol. Rep. (2004) [Pubmed]
  74. Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis. Tefferi, A., Pardanani, A. Int. J. Hematol. (2004) [Pubmed]
  75. Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera. Elliott, M.A., Tefferi, A. Curr. Hematol. Rep. (2004) [Pubmed]
  76. Polycythemia vera: a comprehensive review and clinical recommendations. Tefferi, A. Mayo Clin. Proc. (2003) [Pubmed]
  77. The forgotten myeloproliferative disorder: myeloid metaplasia. Tefferi, A. Oncologist (2003) [Pubmed]
  78. A contemporary approach to the diagnosis and management of polycythemia vera. Tefferi, A. Curr. Hematol. Rep. (2003) [Pubmed]
  79. Anemia in adults: a contemporary approach to diagnosis. Tefferi, A. Mayo Clin. Proc. (2003) [Pubmed]
  80. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Tefferi, A., Mesa, R.A., Gray, L.A., Steensma, D.P., Camoriano, J.K., Elliott, M.A., Pardanani, A., Ansell, S.M., Call, T.G., Colon-Otero, G., Schroeder, G., Hanson, C.A., Dewald, G.W., Kaufmann, S.H. Blood (2002) [Pubmed]
  81. A long-term retrospective study of young women with essential thrombocythemia. Tefferi, A., Fonseca, R., Pereira, D.L., Hoagland, H.C. Mayo Clin. Proc. (2001) [Pubmed]
  82. Recent progress in the pathogenesis and management of essential thrombocythemia. Tefferi, A. Leuk. Res. (2001) [Pubmed]
  83. The pathogenesis of chronic myeloproliferative diseases. Tefferi, A. Int. J. Hematol. (2001) [Pubmed]
  84. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Tefferi, A., Mesa, R.A., Schroeder, G., Hanson, C.A., Li, C.Y., Dewald, G.W. Br. J. Haematol. (2001) [Pubmed]
  85. Spontaneous pneumomediastinum and subcutaneous emphysema complicating bronchiolitis obliterans after allogeneic bone marrow transplantation--case report and review of literature. Kumar, S., Tefferi, A. Ann. Hematol. (2001) [Pubmed]
  86. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Tefferi, A., Murphy, S. Blood Rev. (2001) [Pubmed]
  87. Myelofibrosis with myeloid metaplasia. Tefferi, A. N. Engl. J. Med. (2000) [Pubmed]
WikiGenes - Universities